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Background: To evaluate the association between urinary MyProstateScore (MPS) 2 
and pathologic grade group (GG) at surgery in men diagnosed with GG1 prostate 3 
cancer (PCa) on biopsy.  4 
 5 
Methods: Using an institutional biospecimen protocol, we identified men with GG1 PCa 6 
on biopsy and PSA ≤10 ng/ml who underwent radical prostatectomy (RP) at the 7 
University of Michigan. MPS was retrospectively calculated using prospectively 8 
collected, post-DRE urine samples. The primary outcome was upgrading on RP 9 
pathology, defined as GG≥2. The associations of MPS, PSA, and PSA density (PSAD) 10 
with upgrading were assessed on univariable logistic regression, and the predictive 11 
accuracy of each marker was estimated by the area under the receiver operating 12 
characteristic curve (AUC).  13 
 14 
Results: There were 52 men with urinary specimens available that met study criteria, 15 
based on biopsy Gleason Grade and specimen collection. At RP, 17 men (33%) had 16 
GG1 cancer and 35 (67%) had GG≥2 cancer. Preoperative MPS was significantly 17 
higher in patients with GG≥2 cancer at surgery (median 37.8 [IQR, 22.2-52.4]) as 18 
compared to GG1 (19.3 [IQR, 9.2-29.4]; p=0.001). On univariable logistic regression, 19 
increasing MPS values were significantly associated with upgrading (odds ratio 1.07 per 20 
one-unit MPS increase, 95% CI 1.02-1.12, p=0.004), while PSA and PSAD were not 21 
significantly associated with upgrading. Similarly, the discriminative ability of the MPS 22 
model (AUC 0.78) for upgrading at RP was higher compared to models based on PSA 23 
(AUC 0.52) and PSAD (AUC 0.62).  24 
 25 
Conclusions: In men diagnosed with GG1 PCa who underwent surgery, MPS was 26 
significantly associated with RP cancer grade. In this limited cohort of men, these 27 
findings suggest that MPS could help identify patients with undetected high-grade 28 













Although screening with serum prostate-specific antigen (PSA) has been shown to 3 
reduce prostate cancer (PCa) mortality (1–3), PSA is poorly specific for PCa diagnosis 4 
and clinically-significant PCa (Grade Group ≥2 [GG≥2]), such that a significant subset of 5 
biopsies performed prove to be unnecessary (i.e. negative or GG1) (4). As such, there 6 
is substantial need to better define the risk and detection of GG≥2 cancer in men 7 
traditionally referred for prostate biopsy, thereby sparing patients without cancer and 8 
those with low-grade disease from invasive, costly, and anxiety-provoking PCa 9 
evaluation (5).  10 
 11 
Supplementing serum PSA with additional, cancer-specific biomarkers is one potential 12 
solution. The noncoding RNA Prostate Cancer Antigen 3 (PCA3) and the 13 
TMPRSS2:ERG (T2:ERG) gene fusion are two such cancer-specific markers, both of 14 
which are readily detectable in urine. Consequently, novel urinary assays quantifying 15 
these markers have demonstrated their association with GG≥2 PCa detection across 16 
initial and repeat biopsy settings (6–10). Furthermore, Sanda and colleagues 17 
demonstrated that combined testing with urinary PCA3 and T2:ERG could have 18 
prevented 42% of unnecessary biopsies, while failing to detect only 7% of GG≥2 19 
cancers (11). Formerly named the Mi-Prostate Score (MiPS), the MyProstateScore 20 
(MPS) test combines these markers with serum PSA in a multivariable regression 21 
model. Initial validation in 1244 men showed that MPS provided superior predictive 22 
accuracy for GG≥2 cancer relative to PSA plus clinical variables (i.e. the Prostate 23 
 5 
Cancer Prevention Trial high-grade [PCPThg] risk calculator). Additionally, the use of 1 
MPS was associated with a 35-47% reduction in prostate biopsy on decision curve 2 
analysis (DCA) while delaying diagnosis in only 1.0-2.3% of GG≥2 cases (12). More 3 
recently, the MPS threshold of 10 was shown to rule out GG≥2 cancer with 97% 4 
sensitivity and 98% negative predictive value (NPV) in two large validation populations. 5 
 6 
While MPS appears to be highly accurate for detection of GG≥2 cancer, prostate biopsy 7 
is an imperfect reference standard for pathologic grading. Specifically, standard prostate 8 
biopsy misses an estimated 15-20% of cancers and underestimates cancer grade 9 
relative to final radical prostatectomy (RP) pathology (13–15). While the vast majority of 10 
patients with GG≥2 PCa undergo definitive treatment, under-grading on biopsy is most 11 
concerning in patients diagnosed with GG1 disease, as this population largely defers 12 
treatment in favor of active surveillance (16). Therefore, there is a need for methods of 13 
identifying GG1 patients harboring more aggressive, undetected disease on biopsy. 14 
Although previous studies have focused on using MPS to rule out clinically significant 15 
PCa in biopsy-naïve men, MPS may play a role in risk stratifying those with GG1 16 
disease. As such, in a retrospective sample of patients with biopsy-detected GG1 17 
cancer, we explored the association of pre-operative MPS with cancer grade in the 18 
radical prostatectomy based surgical pathology specimen – the gold standard for 19 







Study cohort  3 
Since 2008, first-catch, post-DRE urine specimens have been prospectively collected at 4 
our institution prior to prostate biopsy under an IRB-approved protocol. Specimens are 5 
mixed with RNA stabilization buffer and stored at -70°C prior to processing (11,12). For 6 
the current study, we identified patients with urine specimens available for MPS testing 7 
who had PSA≤10, GG1 PCa on biopsy, and proceeded to RP within one year of biopsy 8 
and urine collection. Of 56 eligible cases, MPS testing was informative in 52 (93%), 9 
yielding the study cohort. 10 
 11 
Clinical Approach 12 
Demographic and clinical data are recorded per protocol and were confirmed prior to 13 
analysis. All patients underwent standard 12-core transrectal ultrasound (TRUS) guided 14 
systematic biopsy. In patients that underwent multiparametric MRI (mpMRI), findings 15 
were reported in accordance with the prostate imaging reporting and data system (PI-16 
RADS) v2 (17). Five out of six patients with PI-RADS ≥3 lesions underwent targeted 17 
biopsy. Biopsy and RP specimens were graded according to ISUP Grade Group per 18 
standard practice (18). 19 
 20 
MPS testing 21 
MPS was retrospectively calculated for all eligible cases as previously described (12). In 22 
brief, transcription-mediated amplification yielded PCA3, T2:ERG, and PSA mRNA (8). 23 
 7 
PCA3 and T2:ERG scores were generated by normalization to PSA mRNA, and MPS 1 
was calculated using validated, locked models including serum PSA, PCA3 score, and 2 
T2:ERG score (12). The MPS assay provides a continuous score from 0 (very unlikely 3 
to detect GG≥2 PCa) to 100 (very likely to detect GG≥2 PCa).  4 
 5 
Statistical Analysis 6 
The primary outcome was detection of GG≥2 cancer on final radical prostatectomy 7 
based surgical pathology (i.e. upgrading). Demographic and clinical characteristics were 8 
compared by upgrading status using the Wilcoxon rank-sum test for continuous 9 
variables and Fisher’s exact test for proportions. The association of patient-level factors 10 
with upgrading was assessed on univariable logistic regression analysis, yielding odds 11 
ratios (ORs) and 95% confidence intervals (CIs). The discriminative accuracy of PSA-, 12 
PSAD-, and MPS-based models for upgrading were quantified by the area under the 13 
receiver operating characteristic curve (AUC). To account for baseline demographic 14 
variables, we secondarily assessed multivariable models including the PCPThg-rc (i.e. 15 
PSA plus clinical factors). Tumor size (maximum tumor dimension in centimeters) was a 16 
secondary outcome, and the correlation of MPS with tumor size was evaluated using 17 
the Spearman correlation coefficient. Finally, we explored the association of MPS 18 
values with adverse pathologic features, including: GG³3, pT stage ³3 (seminal vesicle 19 
invasion [SVI] or extra prostatic extension [EPE]), pN1, or a positive surgical margin 20 






Study population 3 
Of the 52 men with biopsy GG1 who underwent RP, 35 (67%) upgraded to GG≥2 4 
cancer on final surgical pathology. Table 1 presents demographic and clinical 5 
characteristics of the overall cohort. Age, race, family history, and history of negative 6 
prostate biopsy did not significantly differ by RP grade. Notably, preoperative PSA 7 
(median 4.3 vs. 4.7, p=0.8) and PSAD (median 0.09 vs. 0.11, p=0.17) did not 8 
significantly differ between patients with and without upgrading at RP, respectively. By 9 
contrast, median PCA3 (15.3 vs. 41.5, p<0.001), T2:ERG (26.0 vs. 58.1, p=0.03), and 10 
MPS (19.3 vs. 37.8, p=0.001) were significantly higher in cases of pathological 11 
upgrading. MPS values by pathological grade group are illustrated in Figure 1.  12 
 13 
Logistic regression models for GG≥2 cancer at RP 14 
Univariable logistic regression was performed on demographic and biochemical 15 
variables (Table 2). Demographic variables (i.e. age, abnormal DRE, previous negative 16 
biopsy, family history, PCPThg-rc, and number of positive cores), PSA, and PSAD were 17 
not associated with GG³2 PCa. Meanwhile, MPS values were significantly associated 18 
with tumor upgrading (OR 1.07 per one-unit MPS increase, 95% CI 1.02-1.12, p=0.004). 19 
The discriminative accuracy of PSA (AUC 0.52) and PSAD (AUC 0.62) were poor, while 20 
MPS yielded an AUC of 0.78. Corresponding ROC curves for these biomarker-based 21 
models are illustrated in Figure 2. Similarly, relative to the PCPThg-rc (AUC 0.57) and 22 
 9 
PCPThg-rc + prostate volume (AUC 0.70), the MPS-based PCPThg-rc model 1 
demonstrated superior predictive accuracy (AUC 0.80) (Supplementary Figure 1).  2 
 3 
MPS and Secondary RP Outcomes 4 
Among our cohort of 52 patients, 17 (33%) had GG1, 29 (56%) had GG2 without 5 
adverse pathology, and 6 (12%) had GG2 and/or GG3 with adverse pathology at RP. 6 
No patients with GG1 at RP were found to have adverse pathological features. Among 7 
the 35 men with GG³2, three patients had positive surgical margins, two had GG3 8 
disease, and one had EPE. Interestingly, MPS values increased from a median of 19.3 9 
(IQR, 9.2 - 29.4) in GG1 men and 35.1 (IQR, 21.7 - 45.5) in GG2 men without adverse 10 
features to 62.0 (IQR, 52.0 - 67.1) in GG2 men with adverse pathology (Table 3). 11 
Additionally, MPS values were compared by dominant tumor size for all 52 men 12 
(median 1.25 cm [IQR, 0.85 - 1.65 cm]), and the Spearman rank-order correlation 13 
between MPS and RP tumor volume demonstrated statistical significance (r=0.347, 14 












Given the well-studied risks and limitations of prostate biopsy (4,21,22), the need for 3 
novel biomarkers to aid in diagnosis of GG≥2 PCa remains prominent. The urinary MPS 4 
test has previously been validated for improved detection of GG≥2 cancer on biopsy 5 
relative to PSA and clinical risk factors (PCPThg-rc) (12). However, standard prostate 6 
biopsy is estimated to miss cancer in 15-20% of men, and relative to RP pathology, fails 7 
to identify the highest-grade cancer in approximately one-third of cases (15). This is 8 
particularly concerning for men diagnosed with GG1 PCa, where active surveillance 9 
(AS) may be recommended based on the presumed absence of clinically significant 10 
disease. We therefore sought to explore the association of MPS with cancer grade on 11 
RP pathology – the gold standard for histologic diagnosis – in men diagnosed with GG1 12 
PCa on biopsy. We found that preoperative MPS was significantly higher in men found 13 
to have GG≥2 cancer at RP compared to those who did not (median 37.8 vs. 19.3, 14 
p=0.001). Furthermore, MPS was associated with superior predictive accuracy for 15 
GG≥2 cancer at RP (AUC 0.78) as compared to PSA (AUC 0.52) and PSAD (AUC 16 
0.62).  17 
 18 
While urinary T2:ERG has been associated with biopsy findings in multiple studies, 19 
there are limited data exploring the association of T2:ERG with more definitive 20 
pathologic endpoints. By contrast, several groups have measured the association of 21 
PCA3 with surgical pathology. Although one initial study of 62 patients found no 22 
significant association of PCA3 with pathologic tumor grade or size (23), a larger body 23 
 11 
of evidence supports the association of PCA3 with definitive pathologic outcomes. For 1 
example, in 305 men who underwent RP with biopsy-proven clinically localized PCa, 2 
Auprich et al. found that a PCA3 score cutoff of 24 was strongly associated with GG≥2 3 
cancer (OR 3.3; p<0.001) and tumor volume <0.5 cm3 (OR 0.18; p<0.001) on surgical 4 
pathology (24). Similarly, on multivariable analysis including PCA3 score, PSAD, biopsy 5 
criteria (tumor volume on biopsy), and MRI findings, Ploussard et al. found that a PCA3 6 
score cutoff of 25 was strongly associated with significant PCa (OR 12.7; p=0.003) 7 
based on Epstein criteria and tumor volume ≥0.5 cm3 (OR 5.4; p=0.01) (25). Building 8 
upon these data, we found that the MPS test – combining urinary PCA3 and T2:ERG 9 
with serum PSA – was significantly associated with tumor grade and volume on RP 10 
pathology. Given the association of the PCPThg-rc with cancer in previous studies 11 
(26,27), we confirmed our findings in a multivariable model adjusting for this clinical risk 12 
score. Indeed, the MPS-PCPThg-rc model (AUC 0.80) outperformed PCPThg-rc alone 13 
(AUC 0.57) and PCPThg-rc + prostate volume (AUC 0.70). 14 
 15 
In addition to improving the diagnostic pathway, it is possible that emerging tools such 16 
as MPS could help guide management decisions after diagnosis, particularly in men 17 
with GG1 disease (28). For instance, a particularly high MPS score could suggest the 18 
presence of higher-grade cancer not detected on biopsy. Clinically, such findings could 19 
prompt earlier confirmatory biopsy or additional assessment with MRI prior to enrollment 20 
in active surveillance. Currently, no available diagnostic or prognostic tools provide 21 
sufficient evidence to consider forgoing early repeat biopsy in these patients (29,30). 22 
Consistent with prior studies highlighting the association of PCA3 and upgrading during 23 
 12 
AS (31,32), our findings suggest that MPS could have a potential role as a non-invasive 1 
tool to reduce the morbidity of monitoring during AS. It is also conceivable that a test 2 
capable of predicting non-organ confined disease could have implications for initial 3 
management decisions. Such an application would require a high level of evidence in 4 
the appropriate clinical populations. Still, it is encouraging that MPS was highly elevated 5 
in the minority of patients with RP GG³3 disease or other adverse pathological features 6 
(pT³3, pN1, or positive surgical margin). 7 
 8 
The current study has notable limitations. First, limiting our cohort to men with PSA ≤10 9 
ng/ml would be expected to reduce the predictive accuracy of all the studied markers. 10 
Given that PSA is a component of MPS testing as well, these data can be interpreted to 11 
reflect the incremental knowledge provided by MPS relative to PSA alone and PSAD in 12 
this clinical reference range. Moreover, this population was chosen to specifically 13 
assess the association of MPS with cancer grade in patients with similar, low-risk 14 
features at diagnosis (i.e. GG1 and PSA ≤10 ng/ml) eligible for AS. As MPS appears to 15 
reflect the underlying “true” cancer state, these data support additional study of RP 16 
pathology and longer-term clinical outcomes across PSA ranges. Additionally, our 17 
sample size was limited, which would have restricted the number of factors included in 18 
multivariable models. We were however able to account for baseline clinical factors 19 
using the single composite PCPThg-rc, and MPS outperformed PSA and PSAD in both 20 
the univariable and multivariable analyses. Still, the current analysis was not intended to 21 
drive clinical application, but rather to provide initial confirmation of the association of 22 
MPS with GG≥2 cancer in a more definitive histopathologic reference than biopsy – the 23 
 13 
gold standard RP specimen. Additional data are needed to corroborate these findings 1 

























In a cohort of men with biopsy confirmed GG1 cancer who underwent RP, we found that 3 
urinary MPS was significantly associated with cancer grade on final pathology. MPS 4 
provided substantially stronger discriminative ability for pathologic tumor grade in this 5 
population compared to PSA and PSAD. These data support a potential role for MPS in 6 
identifying the presence of occult, clinically significant PCa in the setting of low-risk 7 
cancer on biopsy. Additional studies are warranted to confirm these findings and better 8 
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Table 1. Clinical and pathological characteristics of 52 men diagnosed with GG1 prostate cancer 
treated with RP. 
 
 Overall Not upgraded Upgraded p-value  
N 52 (100%) 17 (33%) 35 (67%)   
Clinical Characteristics      
Age  62.0 (54.5 - 66.9) 58.5 (54.0 - 66.9) 62.3 (55.9 - 66.8) 0.6  
African American race 6 (12%) 2 (12%) 4 (11%) > 0.9  
Abnormal DRE 9 (17%) 2 (12%) 7 (20%) 0.7  
Family history 14 (29%) 5 (31%) 9 (27%) > 0.9  
Prior negative biopsy 10 (19%) 3 (18%) 7 (20%) > 0.9  
PCPThg-rc (%) 9.6 (6.5 - 14.6) 8.3 (6.6 - 13.3) 10.2 (6.5 – 15.0) 0.5  
Year of biopsy 2014 (2012 - 2016) 2012 (2011 - 2014) 2015 (2013 - 2017) 0.004  
Biomarkers      
PSA (ng/mL) 4.6 (3.8 - 6.4) 4.3 (4.0 - 6.1) 4.7 (3.7 - 6.4) 0.8  
PSA density (ng/mL/mL) 0.10 (0.07 - 0.15) 0.09 (0.06 - 0.13) 0.11 (0.08 - 0.18) 0.17  
PCA3 33.0 (15.2 - 76.9) 15.3 (11.0 - 24.8) 41.5 (20.7 - 88.8) < 0.001  
T2:ERG 40.5 (13.8 - 103.7) 26.0 (11.0 - 47.4) 58.1 (15.9 - 173.7) 0.03  
MPS 32.6 (18.7 - 48.3) 19.3 (9.2 - 29.4) 37.8 (22.2 - 52.4) 0.001  
Imaging      
Underwent MRI 
       PI-RADS ≤2 
       PI-RADS 3 
       PI-RADS 4 

















Biopsy Results      
Prostate volume on TRUS (mL) 44.0 (34.8 - 53.8) 46.7 (42.0 - 63.3) 41.0 (31.0 - 53.1) 0.04  
Positive systematic cores (n) 2.5 (1.0 - 4.0) 2.0 (1.0 - 3.0) 3.0 (2.0 - 4.0) 0.047  
Maximum core involvement (%) 25 (8.5 - 50) 15 (5.0 - 40) 30 (9.0 - 50) 0.18  
Values displayed as median (IQR) or n (%). DRE: digital rectal examination; PCPThg-rc: Prostate Cancer 
Prevention Trial high grade risk calculator; PSA: prostate-specific antigen; PCA3: Prostate Cancer Antigen 3; 
T2:ERG: TMPRSS2:ERG gene fusion; MPS: MyProstateScore; PI-RADS: prostate imaging reporting and data 




















Figure 1. Distributions of MPS scores in patients who did (GG³2) or did not (GG1) upgrade on RP 







































Grade Group on Surgical Pathology
Table 2. Univariable analyses of clinical variables and biomarkers in predicting the probability of 
















OR: odds ratio; 95% CI: 95% confidence interval; DRE: digital rectal examination; PCPThg-rc: Prostate Cancer 
Prevention Trial high grade risk calculator; PSA: prostate-specific antigen; PSAD: PSA density; PCA3: Prostate 
































 Univariable Analysis  
Predictors OR (95% CI) p-value  
Age 1.02 (0.95 – 1.10) 0.6  
Abnormal DRE 1.88 (0.35 – 10.18) 0.5  
Prior Negative Biopsy 1.17 (0.26 – 5.21) 0.8  
Family History 0.83 (0.22-3.04) 0.8  
PCPThg-rc 1.03 (0.93-1.13) 0.6  
Number of positive cores 1.36 (0.94-1.97) 0.11  
    
PSA 0.99 (0.75 – 1.30) 0.9  
PSAD 1.07 (0.97 – 1.18) 0.15  
PCA3 1.03 (1.01 – 1.06) 0.02  
T2:ERG 1.00 (1.00 – 1.01) 0.2  
MPS 1.07 (1.02 – 1.12) 0.004  
Figure 2. Receiver operating characteristics curve for PSA-, PSAD-, and MPS-based univariable 



















































Table 3. MPS scores of patients based on RP tumor grade and the presence or absence of adverse 
pathological features. 
 
RP Outcome N (%) MPS (median, IQR) 
GG1 17 (33%) 19.3 (9.2 – 29.4) 
GG2 without adverse pathology 29 (56%) 35.1 (21.7 – 45.5) 
GG³2 with adverse pathology  6 (12%) 62.0 (52.0 – 67.1) 












































Supplementary Figure 1. Receiver operating characteristics curve for PCPThg-rc-based 
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